China’s cancer breakthroughs rattle pharma—and washington sounds the alarm
The gist
China’s biotech surge is shaking up global cancer care—and Washington is scrambling to keep up as Akeso’s new antibody therapy outpaces Western rivals and triggers regulatory alarms.
What to know
- Akeso’s bispecific antibody ivonescimab cut lung cancer death risk by 34% in Phase 3 trials, outshining Keytruda and Avastin with a median survival of 27.9 months.
- Chinese biotechs, now oncology innovators, stunned the ASCO 2026 stage with multiple Phase 3 wins, signaling a new era of competition for Big Pharma.
- US lawmakers and regulators are cracking down on Chinese biotech deals, proposing tighter FDA oversight and national security reviews to safeguard American innovation.
China’s Oncology Power Shift
China’s cancer drug breakthroughs are forcing a global rethink as Akeso’s ivonescimab not only outperforms Western standards, but also sparks debate over the challenges of translating China-only clinical results into worldwide practice.
Akeso’s PD-1/VEGF bispecific antibody ivonescimab has emerged as a groundbreaking therapy in lung cancer, demonstrating a remarkable 34% reduction in the risk of death in the Phase 3 Harmoni-6 trial for squamous non-small-cell lung cancer. By extending median survival to 27.9 months compared to 23.7 months with standard immunotherapy plus chemotherapy, ivonescimab is poised to disrupt the global lung cancer treatment paradigm and challenge established drugs like Merck’s Keytruda and Roche’s Avastin.
The clinical success of ivonescimab has ignited a fierce biotech race, catalyzing major strategic deals and regulatory scrutiny as Chinese companies like Akeso and Innovent transition from being mere suppliers to leaders in oncology innovation. This shift is underscored by multiple positive China-run Phase 3 readouts at ASCO 2026, including Innovent’s claudin-targeted conjugate in gastric cancer, signaling a broader repositioning of China as a powerhouse in global cancer therapeutics.
While ivonescimab’s Phase 3 data set a new global standard by outperforming an approved PD-1 inhibitor in first-line squamous lung cancer, experts like Dr. Suresh Ramalingam caution that the trial’s exclusive Chinese patient population necessitates further global studies to confirm efficacy across diverse demographics. This ongoing debate highlights the complexities of translating China-originated oncology breakthroughs into worldwide clinical practice.
Regulators Tighten Biotech Grip
US lawmakers and agencies are moving to overhaul drug approval, investment, and manufacturing rules to counter China’s biotech ascent, linking patient safety and national security in unprecedented ways.
Amid mounting concerns over China’s state-backed biotech surge and associated intellectual property risks, US regulatory voices are calling for bold FDA leadership to revamp drug approval processes and safeguard domestic innovation. Proposals include adopting an expedited Investigational New Drug (IND) pathway for Phase 1 trials, inspired by Australia’s streamlined system, to cut down the current 12–18 month preclinical bottleneck. Simultaneously, there is a push for stricter enforcement of US ethical and quality standards on foreign clinical and manufacturing sites, particularly in China, where issues such as consent violations in Xinjiang have raised alarms, underscoring the need to level the playing field and protect patient safety.
Legislative initiatives are increasingly intertwining biotech innovation with national security imperatives, as evidenced by a bipartisan House bill seeking to fold biotechnology into the Comprehensive Outbound Investment National Security Act. This move aims to impose rigorous national security reviews on US investments in Chinese biotech firms, directly impacting licensing channels used by pharma giants like Lilly, Merck, AstraZeneca, and BMS. Following high-profile deals such as Pfizer-Metsera and BMS-Hengrui, this legislation reflects a strategic recalibration where Chinese oncology breakthroughs are no longer viewed solely as scientific competition but as potential security exposures that introduce new timing and operational risks for Western companies.
To further fortify domestic biotech competitiveness, there is advocacy for codifying the National Priority Voucher program with stringent criteria mandating US-based preclinical research, manufacturing, and primary clinical trials. This legislative tightening aims to incentivize onshore development and reduce reliance on foreign sites, particularly in China, thereby aligning innovation incentives with national security priorities. Complementing these efforts, the FDA is also urged to establish clear, predictable regulatory pathways for emerging clinical AI technologies, balancing rapid innovation with robust patient safety benchmarks, signaling a comprehensive approach to modernizing US biotech oversight in the face of global challenges.
Biotech’s Digital Disruption
AI-driven R&D and shifting commercial strategies are upending pharma’s traditional playbook, accelerating drug timelines while demanding new digital infrastructure and global clinical validation.
Pharma's strategic pivot towards PD-1/VEGF bispecific antibodies, highlighted by Akeso's ivonescimab outperforming Keytruda with a 34% reduction in mortality risk in first-line squamous lung cancer, underscores a powerful new modality in oncology drug development. However, emerging expert analysis, such as Souro Chowdhury's observations, questions whether lung cancer is the optimal target, suggesting that cancers more dependent on the VEGF pathway like hepatocellular carcinoma and gastric cancers may yield greater therapeutic payoff. This debate is further complicated by demographic disparities between predominantly older male Chinese trial populations and more diverse Western cohorts, emphasizing the need for broader, globally representative clinical studies to validate efficacy across patient groups.
Technological innovation is radically reshaping biotech R&D and commercialization, with AI-driven integrated workflows slashing drug discovery timelines from five years to just 18 months and accelerating clinical site buildouts by up to two years, thereby bringing therapies to patients significantly faster. Concurrently, evolving commercial dynamics driven by healthcare professional engagement challenges and the rise of consumerization compel pharma companies to rethink marketing strategies, now contending not only with traditional competitors but also digital intermediaries and consumer market forces. Underpinning this transformation is a push towards a streamlined digital infrastructure, centered on a few high-quality systems of record like advanced ERP and CRM platforms, which are essential to enabling an 'agentic future' of seamless, integrated biotech workflows.
